BioMarin Uses Itamar Medical’s Endo-PAT2000 In Successful Phase 2 Study For New Treatment For Sickle Cell Disease

Itamar Medical, an international medical technology company developing noninvasive diagnostic technology using the Peripheral Arterial Tone (PAT?) Signal, announced today the use of the company’s patented Endo-PAT2000 in BioMarin Pharmaceutical Inc.’s phase 2 study of patients with Sickle Cell Disease (SCD). The Endo-PAT2000 was used to measure endothelial function in a study designed to evaluate whether the drug 6R-BH4 can improve endothelial function in SCD patients.

More: continued here

Filed under: Clinical Trials on December 4th, 2008